Item Details

17 Nov 2026

Eli Lilly signs cancer research partnership worth up to $5.9 billion

Announced on 16 November, Eli Lilly has signed a research and licensing agreement with Cambridge based Stipple Bio to develop targeted cancer treatments. The agreement could be worth up to $5.9 billion through milestone payments and royalties. HPC could help connect biotechnology companies with pharmaceutical groups, research partners and investors.

Get in Touch

We’ll get back to you shortly.